| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MTPPA targets inflammatory and pain pathways. Its mechanism of action is not fully detailed in the available literature, but as a compound with anti-inflammatory and pain-relieving effects, it likely modulates inflammatory mediators and pain signaling pathways. It may inhibit the production of pro-inflammatory cytokines or interact with pain receptors. Its exact molecular targets require further investigation.
|
|---|---|
| ln Vitro |
In vitro, MTPPA has been shown to have anti-inflammatory and pain-relieving effects. Its activity is typically assessed in cell-based assays using immune cells stimulated with inflammatory stimuli, where the production of inflammatory cytokines is measured. Its effects on pain pathways can be studied in neuronal cell cultures. However, detailed in vitro potency data are not extensively documented.
|
| ln Vivo |
In vivo, MTPPA is used in research to study inflammation and pain. Its anti-inflammatory and pain-relieving effects suggest potential therapeutic applications, though specific in vivo efficacy data are not detailed in the available literature. The compound is not approved for clinical use.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for MTPPA are not standard, as its mechanism is not fully elucidated. Its anti-inflammatory activity could be assessed by measuring the inhibition of COX or LOX enzymes using cell-free enzyme assays. Its binding to pain receptors could be assessed using radioligand binding studies.
|
| Cell Assay |
In vitro cell-based assays for MTPPA use immune cells, such as macrophages, stimulated with LPS to induce inflammation. Cells are treated with varying concentrations of the compound, and the production of inflammatory cytokines (TNF-α, IL-6, IL-1β) is measured by ELISA. Its effects on pain pathways can be studied in neuronal cell lines by measuring calcium influx or neurotransmitter release.
|
| Animal Protocol |
In vivo animal studies for MTPPA would likely employ models of inflammation and pain, such as carrageenan-induced paw edema or the formalin test. The compound would be administered, and parameters such as paw swelling, pain response, and inflammatory cytokine levels would be assessed. Pharmacokinetic studies in these models would provide information about the compound's absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-[4-(3-methylthien-2-yl)phenyl]propionyloxy]oxacyclohexane-2-carboxylic acid and 2-[2-[4-(3-methylthien-2-yl)phenyl]propionyloxyamino]ethanesulfonic acid. MTPPA has a molecular weight of 246.32 g/mol and a molecular formula of C₁₄H₁₄O₂S. It is also known as M 5011. The compound should be stored under appropriate conditions, typically at -20°C, protected from light and moisture. Its purity is typically >98% by HPLC. Detailed pharmacokinetic parameters such as half-life, volume of distribution, and clearance have not been extensively characterized. |
| Toxicity/Toxicokinetics |
The toxicity profile of MTPPA has not been comprehensively evaluated in published studies. As a research compound, it is not intended for human therapeutic use without further safety evaluation. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
MTPPA is a compound with anti-inflammatory and pain-relieving effects. It is also known as M 5011. Not approved for clinical use; intended for research purposes only.
|
| Molecular Formula |
C14H14O2S
|
|---|---|
| Molecular Weight |
246.324762821198
|
| Exact Mass |
246.071
|
| CAS # |
70991-61-6
|
| PubChem CID |
12769847
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
379.5±30.0 °C at 760 mmHg
|
| Flash Point |
183.3±24.6 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.596
|
| LogP |
3.87
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
271
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)C(C)C1=CC=C(C2=C(C)C=CS2)C=C1
|
| InChi Key |
DTOPKPBTCXKNFF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14O2S/c1-9-7-8-17-13(9)12-5-3-11(4-6-12)10(2)14(15)16/h3-8,10H,1-2H3,(H,15,16)
|
| Chemical Name |
2-[4-(3-methylthiophen-2-yl)phenyl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0598 mL | 20.2988 mL | 40.5976 mL | |
| 5 mM | 0.8120 mL | 4.0598 mL | 8.1195 mL | |
| 10 mM | 0.4060 mL | 2.0299 mL | 4.0598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
